Rachel Galot

440 total citations
26 papers, 221 citations indexed

About

Rachel Galot is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Rachel Galot has authored 26 papers receiving a total of 221 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 8 papers in Oncology and 8 papers in Cancer Research. Recurrent topics in Rachel Galot's work include Lung Cancer Treatments and Mutations (10 papers), Cancer Genomics and Diagnostics (8 papers) and Head and Neck Cancer Studies (6 papers). Rachel Galot is often cited by papers focused on Lung Cancer Treatments and Mutations (10 papers), Cancer Genomics and Diagnostics (8 papers) and Head and Neck Cancer Studies (6 papers). Rachel Galot collaborates with scholars based in Belgium, United States and France. Rachel Galot's co-authors include Jean‐Pascal Machiels, Cédric van Marcke, Nisha Limaye, Antonella Mendola, Raphaël Helaers, Jérôme Ambroise, Lisa Licitra, Miikka Vikkula, Christophe Le Tourneau and Rose‐Marie Goebbels and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Annals of Oncology.

In The Last Decade

Rachel Galot

20 papers receiving 218 citations

Peers

Countries citing papers authored by Rachel Galot

Since Specialization

Citations

This map shows the geographic impact of Rachel Galot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rachel Galot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rachel Galot more than expected).

Fields of papers citing papers by Rachel Galot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rachel Galot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rachel Galot. The network helps show where Rachel Galot may publish in the future.

Co-authorship network of co-authors of Rachel Galot

This figure shows the co-authorship network connecting the top 25 collaborators of Rachel Galot. A scholar is included among the top collaborators of Rachel Galot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rachel Galot. Rachel Galot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Tumor-Informed ctDNA Assay to Predict Outcome in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated with PD-1 Inhibitor 2025 ·Clinical Cancer Research ·(unknown), George Laliotis, Vasily N. Aushev, Sharlene Velichko, Charuta C. Palsuledesai, (unknown), Cédric van Marcke, Rachel Galot, Minetta C. Liu, Jean‐Pascal Machiels	0
2	State of the art and future directions in the treatment of metastatic adenoid cystic carcinoma 2025 ·Current Opinion in Oncology ·Rachel Galot, Jean-Pascal H. Machiels	0
3	1016eTiP A first-in-human phase I study of LY4066434, a potent and orally bioavailable pan-KRAS inhibitor, in KRAS-mutant solid tumors (Trial in Progress) 2025 ·Annals of Oncology ·(unknown), (unknown), (unknown), Takahiko Koyama, Apurvasena Parikh, (unknown), (unknown), Rachel Galot, Ju Hee Lee, (unknown), Davide Melisi, (unknown), Philippe A. Cassier, Li J, (unknown), Jennifer Wright, (unknown), M. Axelson, Nehal J. Lakhani	0
4	925MO First-in-human phase I/Ib study of the oral Werner (WRN) helicase inhibitor HRO761 in patients (pts) with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced solid tumors: Interim safety and efficacy analysis from HRO761 single agent dose escalation 2025 ·Annals of Oncology ·Michael B. Foote, Jingjing Li, Daniel Shao-Weng Tan, Aitana Calvo, Rachel Galot, Elena Garralda, Tormod Kyrre Guren, Antoine Italiano, (unknown), Zev A. Wainberg, Jeffrey Yachnin, Timothy A. Yap, Ruben de Kanter, Nuno Grande, (unknown), Dragana Janković, Laurent Sansregret, Chao Zhang, Ankur K. Nagaraja, Yasutoshi Kuboki	0
5	Tumor-informed ctDNA assay to predict recurrence in locally advanced squamous-cell carcinoma of the head and neck (SCCHN) 2025 ·ESMO Open ·(unknown), George Laliotis, Vasily N. Aushev, (unknown), Charuta C. Palsuledesai, (unknown), Cédric van Marcke, Rachel Galot, Min Liu, J-P. Machiels	3
6	Final results from the phase Ia/Ib study of the novel bromodomain and extra-terminal domain inhibitor, BI 894999, in patients with advanced solid tumors or diffuse large B-cell lymphoma 2025 ·ESMO Open ·Ulrich M. Lauer, Ahmad Awada, (unknown), Geoffrey I. Shapiro, Catherine Thiéblemont, Sarina A. Piha‐Paul, (unknown), Dale R. Shepard, Lara Iglesias Docampo, Rachel Galot, Sylvie Rottey, (unknown), Kristell Marzin, (unknown), Patrick Schöffski	3
7	Sotorasib plus panitumumab for pre-treated non-small cell lung cancer with KRASG12C mutation: A phase 1b study. 2024 ·Journal of Clinical Oncology ·Corey J. Langer, Rachel Galot, Hans Prenen, David S. Hong, Iván Victoria, Ravi Salgia, Maxime Chénard-Poirier, Muhammad Furqan, Emily Chan, (unknown), Caihong Xia, Bob T. Li	1
8	Phase 1 dose-finding study to evaluate safety and tolerability of CVGBM in patients with newly diagnosed and surgically resected MGMT-unmethylated glioblastoma. 2024 ·Journal of Clinical Oncology ·Ghazaleh Tabatabai, Louisa von Baumgarten, Martin J. van den Bent, Michael C. Burger, Pierre Frères, Martin Glas, Peter Hau, Ulrich Herrlinger, Iris Mildenberger, Bart Neyns, Henning Schäfer, Clemens Seidel, Rachel Galot, Antje Wick, Martin Falk, (unknown), (unknown), Sven D. Koch, (unknown), (unknown), (unknown)	3
9	143 (PB131): Preliminary Safety and Pharmacokinetics of the MET-TKI DO-2 in Patients with Advanced Solid Tumors Harboring MET Aberrations: A Phase I Study 2024 ·European Journal of Cancer ·Tim Perera, (unknown), (unknown), Peter de Bruijn, (unknown), Rachel Galot, (unknown), (unknown), Sylvie Rottey, (unknown), (unknown), Berber Piet, C. van Herpen, (unknown), (unknown), Jaap Verweij, (unknown), (unknown), (unknown)	1
10	Results From First-in-Human Phase I Dose-Escalation Study of a Novel Bicycle Toxin Conjugate Targeting EphA2 (BT5528) in Patients With Advanced Solid Tumors 2024 ·Journal of Clinical Oncology ·Babar Bashir, Judy S. Wang, Gerald S. Falchook, Elisa Fontana, Hendrik‐Tobias Arkenau, Louise Carter, Rachel Galot, Bristi Basu, Alastair Greystoke, Vivek Subbiah, Debra L. Richardson, (unknown), Gavin Bennett, (unknown), Hongmei Xu, (unknown), Cong Xu, Carly Campbell, Meredith McKean	8
11	2028TiP Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) + ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3 2023 ·Annals of Oncology ·Julien Mazières, M. Duruisseaux, (unknown), Chigusa Morizane, Rachel Galot, Sylvie Rottey, Jan Stratmann, Yuchao Ma, (unknown), (unknown), Martin Wermke	1
12	Tumor-agnostic plasma assay for circulating tumor DNA detects minimal residual disease and predicts outcome in locally advanced squamous cell carcinoma of the head and neck 2023 ·Annals of Oncology ·(unknown), Cédric van Marcke, Rachel Galot, Raphaël Helaers, Jérôme Ambroise, Aline van Maanen, Antonella Mendola, (unknown), Étienne Marbaix, P. Van Eeckhout, E. Longton, Michèle Magremanne, Sandra Schmitz, Nisha Limaye, J-P. Machiels	22
13	Abstract C152: Preclinical and emerging Phase 1 study data indicates that novel deuterated MET kinase inhibitor DO-2 mitigates the side effects seen with current approved MET kinase inhibitors: Preventing deleterious ‘de-hinging’ to improve tolerability 2023 ·Molecular Cancer Therapeutics ·Timothy Perera, Laurence Mévellec, Hans Prenen, (unknown), Debbie Robbrecht, Sander Bins, (unknown), Peter de Bruijn, Jean‐Pascal Machiels, Rachel Galot, (unknown), (unknown), Irena Loryan, Yang Hu, (unknown), Jaap Verweij	1
14	858O Minimal residual disease (MRD) diagnosed by a plasma tumor-agnostic circulating tumor DNA (ctDNA) assay after curative therapy in locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN) predicts disease relapse and survival 2023 ·Annals of Oncology ·(unknown), Cédric van Marcke, Rachel Galot, Raphaël Helaers, Aline van Maanen, Jérôme Ambroise, Antonella Mendola, (unknown), Étienne Marbaix, P. Van Eeckhout, E. Longton, Michèle Magremanne, Sandra Schmitz, Nisha Limaye, J-P. Machiels	1
15	935P A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN): Results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM) 2023 ·Annals of Oncology ·Rachel Galot, Christophe Le Tourneau, Lisa Licitra, Caroline Even, Amaury Daste, Stéphanie Henry, Christian Borel, Cyril Abdeddaim, Emmanuel Seront, (unknown), Annemie Rutten, Esma Saâda, Frédéric Rolland, Lorenzo Livi, Pol Specenier, (unknown), (unknown), C. Lefèvre, Ana Joaquim, J-P. Machiels	2
16	Regression of a melanoma brain metastasis that had appeared after immune checkpoint inhibitor discontinuation: a hypothesis-generating case 2023 ·Acta Clinica Belgica ·(unknown), Emmanuel Seront, Rachel Galot, İdil Güneş Tatar, Jean‐François Baurain, (unknown)	1
17	Liquid biopsy for mutational profiling of locoregional recurrent and/or metastatic head and neck squamous cell carcinoma 2020 ·Oral Oncology ·Rachel Galot, Cédric van Marcke, Raphaël Helaers, Antonella Mendola, Rose‐Marie Goebbels, (unknown), Jérôme Ambroise, (unknown), Miikka Vikkula, Nisha Limaye, Jean‐Pascal Machiels	45
18	Current applications and challenges of circulating tumor DNA (ctDNA) in squamous cell carcinoma of the head and neck (SCCHN) 2020 ·Cancer Treatment Reviews ·Rachel Galot, Jean‐Pascal Machiels	17
19	Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach 2018 ·Annals of Oncology ·Rachel Galot, Christophe Le Tourneau, J. Guigay, Lisa Licitra, Ingeborg Tinhofer, Anthony Kong, Carmela Caballero, Catherine Fortpied, Jan Bogaerts, Anne-Sophie Govaerts, (unknown), Tiana Raveloarivahy, (unknown), (unknown), Esma Saâda-Bouzid, J.-P. Machiels	48
20	Unusual presentation of bladder cancer resurgence and efficacy of radiotherapy 2016 ·BMJ Case Reports ·Rachel Galot, Nicolas Christian, (unknown), Emmanuel Seront	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact